Antitumor activity of a novel homodimeric SMAC mimetic in ovarian carcinoma

Molecular Pharmaceutics

Volumn 11, Issue 1, 2014, Pages 283-293

  Gatti, Laura ^a   De Cesare, Michelandrea ^a   Ciusani, Emilio ^b   Corna, Elisabetta ^a   Arrighetti, Noemi ^a   Cominetti, Denis ^a   Belvisi, Laura ^c   Potenza, Donatella ^c   Moroni, Elisabetta ^c   Vasile, Francesca ^c   Lecis, Daniele ^a   Delia, Domenico ^a   Castiglioni, Vittoria ^c   Scanziani, Eugenio ^c   Seneci, Pierfausto ^c   Zaffaroni, Nadia ^a   Perego, Paola ^a  

^a NATIONAL CANCER INSTITUTE   (Italy)

^b DEPARTMENT OF NEUROSURGERY   (Italy)

^c UNIVERSITY OF MILAN   (Italy)

Author keywords

apoptosis; ovarian carcinoma; SMAC mimetics; TRAIL

Indexed keywords

ANTINEOPLASTIC AGENT; CALRETICULIN; CASPASE 3; CISPLATIN; DOXORUBICIN; HOMODIMER; MITOXANTRONE; PACLITAXEL; PEPTIDOMIMETIC AGENT; SECOND MITOCHONDRIAL ACTIVATOR OF CASPASE; SM 59; SM 83; TOPOTECAN; TUMOR NECROSIS FACTOR ALPHA; TUMOR NECROSIS FACTOR RELATED APOPTOSIS INDUCING LIGAND; UNCLASSIFIED DRUG; X LINKED INHIBITOR OF APOPTOSIS;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; BREAST CARCINOMA; CANCER GROWTH; CANCER INHIBITION; CANCER SIZE; CARCINOMA CELL; CELL DEATH; COLON CARCINOMA; CONTROLLED STUDY; DOWN REGULATION; DRUG EFFICACY; DRUG MECHANISM; DRUG POTENTIATION; DRUG STRUCTURE; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; HISTOPATHOLOGY; HUMAN; HUMAN CELL; IC 50; IMMUNOGENICITY; IN VITRO STUDY; IN VIVO STUDY; MOUSE; NONHUMAN; NUCLEAR MAGNETIC RESONANCE; OVARY CARCINOMA; PRIORITY JOURNAL; PROTEIN EXPRESSION; TREATMENT DURATION; TREATMENT RESPONSE; TUMOR MICROENVIRONMENT; UPREGULATION; WESTERN BLOTTING;

ANIMALS; ANTINEOPLASTIC AGENTS; APOPTOSIS; APOPTOSIS REGULATORY PROTEINS; BIOMIMETIC MATERIALS; BLOTTING, WESTERN; CARRIER PROTEINS; CELL PROLIFERATION; ENZYME-LINKED IMMUNOSORBENT ASSAY; FEMALE; HUMANS; INTRACELLULAR SIGNALING PEPTIDES AND PROTEINS; MAGNETIC RESONANCE SPECTROSCOPY; MICE; MITOCHONDRIAL PROTEINS; MOLECULAR DYNAMICS SIMULATION; OVARIAN NEOPLASMS; TNF-RELATED APOPTOSIS-INDUCING LIGAND; TUMOR CELLS, CULTURED; TUMOR NECROSIS FACTOR-ALPHA;

EID: 84891751193     PISSN: 15438384     EISSN: 15438392     Source Type: Journal    
DOI: 10.1021/mp4004578     Document Type: Article

References (51)

1. Oberaigner, W.; Minicozzi, P.; Bielska-Lasota, M.; Allemani, C.; de Angelis, R.; Mangone, L.; Sant, M. Eurocare Working Group Survival for ovarian cancer in Europe: The across-country variation did not shrink in the past decade Acta Oncol. 2012, 51, 441-453
2. Baldwin, L. A.; Huang, B.; Miller, R. W.; Tucker, T.; Goodrich, S. T.; Podzielinski, I.; DeSimone, C. P.; Ueland, F. R.; van Nagell, J. R.; Seamon, L. G. Ten-year relative survival for epithelial ovarian cancer Obstet. Gynecol. 2012, 120, 612-618
3. Guarneri, V.; Piacentini, F.; Barbieri, E.; Conte, P. F. Achievements and unmet needs in the management of advanced ovarian cancer Gynecol. Oncol. 2010, 117, 152-158
4. Vaughan, S.; Coward, J. I.; Bast, R. C., Jr; Berchuck, A.; Berek, J. S.; Brenton, J. D.; Coukos, G.; Crum, C. C.; Drapkin, R.; Etemadmoghadam, D.; Friedlander, M.; Gabra, H.; Kaye, S. B.; Lord, C. J.; Lengyel, E.; Levine, D. A.; McNeish, I. A.; Menon, U.; Mills, G. B.; Nephew, K. P.; Oza, A. M.; Sood, A. K.; Stronach, E. A.; Walczak, H.; Bowtell, D. D.; Balkwill, F. R. Rethinking ovarian cancer: recommendations for improving outcomes Nat. Rev. Cancer 2011, 11, 719-725
5. Bast, R. C., Jr; Hennessy, B.; Mills, G. B. The biology of ovarian cancer: New opportunities for translation Nat. Rev. Cancer 2009, 9, 415-428
6. Muggia, F. Platinum compounds 30 years after the introduction of cisplatin: Implications for the treatment of ovarian cancer Gynecol. Oncol. 2009, 112, 275-281
7. Herzog, T. J. The current treatment of recurrent ovarian cancer Curr. Oncol. Rep. 2006, 8, 448-454
8. Perego, P.; Giarola, M.; Righetti, S. C.; Supino, R.; Caserini, C.; Delia, D.; Pierotti, M. A.; Miyashita, T.; Reed, J. C.; Zunino, F. Association between cisplatin resistance and mutation of p53 gene and reduced bax expression in ovarian carcinoma cell systems Cancer Res. 1996, 56, 556-562
9. Plati, J.; Bucur, O.; Khosravi-Far, R. Apoptotic cell signaling in cancer progression and therapy Integr. Biol. 2011, 3, 279-296
10. Kashkar, H. X-linked inhibitor of apoptosis: A chemoresistance factor or a hollow promise Clin. Cancer Res. 2010, 16, 4496-4502
11. Harada, H.; Grant, S. Apoptosis regulators Rev. Clin. Exp. Hematol. 2003, 7, 117-138
12. Chen, D. J.; Huerta, S. Smac mimetics as new cancer therapeutics Anticancer Drugs 2009, 20, 646-658
13. Manzoni, L.; Belvisi, L.; Bianchi, A.; Conti, A.; Drago, C.; de Matteo, M.; Ferrante, L.; Mastrangelo, E.; Perego, P.; Potenza, D.; Scolastico, C.; Servida, F.; Timpano, G.; Vasile, F.; Rizzo, V.; Seneci, P. Homo- and heterodimeric Smac mimetics/IAP inhibitors as in vivo-active pro-apoptotic agents. Part I: Synthesis Bioorg. Med. Chem. 2012, 20, 6687-6708
14. Lecis, D.; Mastrangelo, E.; Belvisi, L.; Bolognesi, M.; Civera, M.; Cossu, F.; De Cesare, M.; Delia, D.; Drago, C.; Manenti, G.; Manzoni, L.; Milani, M.; Moroni, E.; Perego, P.; Potenza, D.; Rizzo, V.; Scavullo, C.; Scolastico, C.; Servida, F.; Vasile, F.; Seneci, P. Dimeric Smac mimetics/IAP inhibitors as in vivo-active pro-apoptotic agents. Part II: Structural and biological characterization Bioorg. Med. Chem. 2012, 20, 6709-6723
15. Johnstone, R. W.; Frew, A. J.; Smyth, M. J. The TRAIL apoptotic pathway in cancer onset, progression and therapy Nat. Rev. Cancer 2008, 8, 782-798
16. Ichikawa, K.; Liu, W.; Zhao, L.; Wang, Z.; Liu, D.; Ohtsuka, T.; Zhang, H.; Mountz, J. D.; Koopman, W. J.; Kimberly, R. P.; Zhou, T. Tumoricidal activity of a novel anti-human DR5 monoclonal antibody without hepatocyte cytotoxicity Nat. Med. 2001, 7, 954-960
17. Takeda, K.; Stagg, J.; Yagita, H.; Okumura, K.; Smyth, M. J. Targeting death-inducing receptors in cancer therapy Oncogene 2007, 26, 3745-3757
18. Vignati, S.; Codegoni, A.; Polato, F.; Broggini, M. Trail activity in human ovarian cancer cells: Potentiation of the action of cytotoxic drugs Eur. J. Cancer 2002, 38, 177-183
19. Petronelli, A.; Saulle, E.; Pasquini, L.; Petrucci, E.; Mariani, G.; Biffoni, M.; Ferretti, G.; Scambia, G.; Benedetti-Panici, P.; Greggi, S.; Cognetti, F.; Russo, M. A.; Sporn, M.; Testa, U. High sensitivity of ovarian cancer cells to the synthetic triterpenoid CDDO-Imidazolide Cancer Lett. 2009, 282, 214-228
20. Bevis, K. S.; Buchsbaum, D. J.; Straughn, J. M., Jr. Overcoming TRAIL resistance in ovarian carcinoma Gynecol. Oncol. 2010, 119, 157-163
21. Petrucci, E.; Pasquini, L.; Petronelli, A.; Saulle, E.; Mariani, G.; Riccioni, R.; Biffoni, M.; Ferretti, G.; Benedetti-Panici, P.; Cognetti, F.; Scambia, G.; Humphreys, R.; Peschle, C.; Testa, U. A small molecule Smac mimic potentiates TRAIL-mediated cell death of ovarian cancer cells Gynecol. Oncol. 2007, 105, 481-492
22. Petrucci, E.; Pasquini, L.; Bernabei, M.; Saulle, E.; Biffoni, M.; Accarpio, F.; Sibio, S.; Di Giorgio, A.; Di Donato, V.; Casorelli, A.; Benedetti-Panici, P.; Testa, U. A small molecule SMAC mimic LBW242 potentiates TRAIL- and anticancer drug-mediated cell death of ovarian cancer cells PLoS One 2012, 7, e35073-1-e35073-14
23. Mao, H. L.; Pang, Y.; Zhang, X.; Yang, F.; Zheng, J.; Wang, Y.; Liu, P. Smac peptide potentiates TRAIL- or paclitaxel-mediated ovarian cancer cell death in vitro and in vivo Oncol. Rep. 2013, 29, 515-522
24. Probst, B. L.; Liu, L.; Ramesh, V.; Li, L.; Sun, H.; Minna, J. D.; Wang, L. Smac mimetics increase cancer cell response to chemotherapeutics in a TNF-alpha-dependent manner Cell Death Differ. 2010, 17, 1645-1654
25. Greer, R. M.; Peyton, M.; Larsen, J. E.; Girard, L.; Xie, Y.; Gazdar, A. F.; Harran, P.; Wang, L.; Brekken, R. A.; Wang, X.; Minna, J. D. SMAC mimetic (JP1201) sensitizes non-small cell lung cancers to multiple chemotherapy agents in an IAP-dependent but TNF-alpha-independent manner Cancer Res. 2011, 71, 7640-7648
26. Eschenburg, G.; Eggert, A.; Schramm, A.; Lode, H. N.; Hundsdoerfer, P. Smac mimetic LBW242 sensitizes XIAP-overexpressing neuroblastoma cells for TNF-alpha-independent apoptosis Cancer Res. 2012, 72, 2645-2656
27. Nikolovska-Coleska, Z.; Meagher, J. L.; Jiang, S.; Yang, C. Y.; Qiu, S.; Roller, P. P.; Stuckey, J. A.; Wang, S. Interaction of a cyclic, bivalent smac mimetic with the x-linked inhibitor of apoptosis protein Biochemistry 2008, 47, 9811-9824
28. Riedl, S. J.; Renatus, M.; Schwarzenbacher, R.; Zhou, Q.; Sun, C.; Fesik, S. W.; Liddington, R. C.; Salvesen, G. S. Structural basis for the inhibition of caspase-3 by XIAP Cell 2001, 104, 791-800
29. Maestro, version 8.0; Schrödinger, LLC, New York, 2007
30. Case, D. A.; Darden, T. A.; Cheatham, T. E., III; Simmerling, C. L.; Wang, J.; Duke, R. E.; Luo, R.; Merz, K. M.; Pearlman, D. A.; Crowley, M.; Walker, R. C.; Zhang, W.; Wang, B.; Hayik, S.; Roitberg, A.; Seabra, G.; Wong, K. F.; Paesani, F.; Wu, X.; Brozell, S.; Tsui, V.; Gohlke, H.; Yang, L.; Tan, C.; Mongan, J.; Hornak, V.; Cui, G.; Beroza, P.; Mathews, D. H.; Schafmeister, C.; Ross, W. S.; Kollman, P. A. AMBER 9; University of California at San Francisco: San Francisco, CA, 2006.
31. Perego, P.; Romanelli, S.; Carenini, N.; Magnani, I.; Leone, R.; Bonetti, A.; Paolicchi, A.; Zunino, F. Ovarian cancer cisplatin-resistant cell lines: Multiple changes including collateral sensitivity to Taxol Ann. Oncol. 1998, 9, 423-430
32. Grandi, M.; Geroni, C.; Giuliani, F. C. Isolation and characterization of a human colon adenocarcinoma cell line resistant to doxorubicin Br. J. Cancer 1986, 54, 515-518
33. Perego, P.; De Cesare, M.; De Isabella, P.; Carenini, N.; Beggiolin, G.; Pezzoni, G.; Palumbo, M.; Tartaglia, L.; Pratesi, G.; Pisano, C.; Carminati, P.; Scheffer, G. L.; Zunino, F. A novel 7-modified camptothecin analog overcomes breast cancer resistance protein-associated resistance in a mitoxantrone- selected colon carcinoma cell line Cancer Res. 2001, 61, 6034-6037
34. Gatti, L.; Perego, P.; Leone, R.; Apostoli, P.; Carenini, N.; Corna, E.; Allievi, C.; Bastrup, U.; De Munari, S.; Di Giovine, S.; Nicoli, P.; Grugni, M.; Natangelo, M.; Pardi, G.; Pezzoni, G.; Singer, J. W.; Zunino, F. Novel bis-platinum complexes endowed with an improved pharmacological profile Mol. Pharmaceutics 2010, 7, 207-216
35. Benard, J.; Da Silva, J.; De Blois, M. C.; Boyer, P.; Duvillard, P.; Chiric, E.; Riou, G. Characterization of a human ovarian adenocarcinoma line, IGROV1, in tissue culture and in nude mice Cancer Res. 1985, 45, 4970-4979
36. Cassinelli, G.; Lanzi, C.; Petrangolini, G.; Tortoreto, M.; Pratesi, G.; Cuccuru, G.; Laccabue, D.; Supino, R.; Belluco, S.; Favini, E.; Poletti, A.; Zunino, F. Inhibition of c-Met and prevention of spontaneous metastatic spreading by the 2-indolinone RPI-1 Mol. Cancer Ther. 2006, 5, 2388-2397
37. Meyer, B.; Peters, T. NMR spectroscopy techniques for screening and identifying ligand binding to protein receptors Angew. Chem., Int. Ed. 2003, 42, 864-890
38. Potenza, D.; Belvisi, L.; Vasile, F.; Moroni, E.; Cossu, F.; Seneci, P. A NMR and computational study of Smac mimics targeting both the BIR2 and BIR3 domains in XIAP protein Org. Biomol. Chem. 2012, 10, 3278-3287
39. Bockbrader, K. M.; Tan, M.; Sun, Y. A small molecule Smac-mimic compound induces apoptosis and sensitizes TRAIL- and etoposide-induced apoptosis in breast cancer cells Oncogene 2005, 24, 7381-7388
40. Li, L.; Thomas, R. M.; Suzuki, H.; De Brabander, J. K.; Wang, X.; Harran, P. G. A small molecule Smac mimic potentiates TRAIL- and TNFalpha-mediated cell death Science 2004, 305, 1471-1474
41. Emeagi, P. U.; Thielemans, K.; Breckpot, K. The role of SMAC mimetics in regulation of tumor cell death and immunity Oncoimmunology 2012, 1, 965-967
42. Obeid, M.; Tesniere, A.; Ghiringhelli, F.; Fimia, G. M.; Apetoh, L.; Perfettini, J.-L.; Castedo, M.; Mignot, G.; Panaretakis, T.; Casares, N.; Metivier, D.; Larochette, N.; van Endert, P.; Ciccosanti, F.; Piacentini, M.; Zitvogel, L.; Kroemer, G. Calreticulin exposure dictates the immunogenicity of cancer cell death Nature Med. 2007, 13, 54-61
43. Wu, H.; Tschopp, J.; Lin, S. C. Smac mimetics and TNFalpha: A dangerous liaison? Cell 2007, 131, 655-658
44. Krepler, C.; Chunduru, S. K.; Halloran, M. B.; He, X.; Xiao, M.; Vultur, A.; Villanueva, J.; Mitsuuchi, Y.; Neiman, E. M.; Benetatos, C.; Nathanson, K. L.; Amaravadi, R. K.; Pehamberger, H.; McKinlay, M.; Herlyn, M. The novel SMAC mimetic birinapant exhibits potent activity against human melanoma cells Clin. Cancer Res. 2013, 19, 1784-1794
45. Gyrd-Hansen, M.; Meier, P. IAPs: From caspase inhibitors to modulators of NF-kappaB, inflammation and cancer Nat. Rev. Cancer 2010, 10, 561-574
46. Emeagi, P. U.; Van Lint, S.; Goyvaerts, C.; Maenhout, S.; Cauwels, A.; McNeish, I. A.; Bos, T.; Heirman, C.; Thielemans, K.; Aerts, J. L.; Breckpot, K. Proinflammatory characteristics of SMAC/DIABLO-induced cell death in antitumor therapy Cancer Res. 2012, 72, 1342-1352
47. Aymeric, L.; Apetoh, L.; Ghiringhelli, F.; Tesniere, A.; Martins, I.; Kroemer, G.; Smyth, M. J.; Zitvogel, L. Tumor cell death and ATP release prime dendritic cells and efficient anticancer immunity Cancer Res. 2010, 70, 855-858
48. Apetoh, L.; Ghiringhelli, F.; Tesniere, A.; Obeid, M.; Ortiz, C.; Criollo, A.; Mignot, G.; Maiuri, M. C.; Ullrich, E.; Saulnier, P.; Yang, H.; Amigorena, S.; Ryffel, B.; Barrat, F. J.; Saftig, P.; Levi, F.; Lidereau, R.; Nogues, C.; Mira, J.-P.; Chompret, A.; Joulin, V.; Clavel-Chapelon, F.; Bourhis, J.; André, F.; Delaloge, S.; Tursz, T.; Kroemer, G.; Zitvogel, L. Toll-like receptor 4-dependent contribution of the immune system to anticancer chemotherapy and radiotherapy Nature Med. 2007, 13, 1050-1059
49. Apetoh, L.; Tesniere, A.; Ghiringhelli, F.; Kroemer, G.; Zitvogel, L. Molecular interactions between dying tumor cells and the innate immune system determine the efficacy of conventional anticancer therapies Cancer Res. 2008, 68, 4026-4030
50. Lu, J.; Bai, L.; Sun, H.; Nikolovska-Coleska, Z.; McEachern, D.; Qiu, S.; Miller, R. S.; Yi, H.; Shangary, S.; Sun, Y.; Meagher, J. L.; Stuckey, J. A.; Wang, S. SM-164: A novel, bivalent Smac mimetic that induces apoptosis and tumor regression by concurrent removal of the blockade of cIAP-1/2 and XIAP Cancer Res. 2008, 68, 9384-9393
51. Ndubaku, C.; Varfolomeev, E.; Wang, L.; Zobel, K.; Lau, K.; Elliott, L. O.; Maurer, B.; Fedorova, A. V.; Dynek, J. N.; Koehler, M.; Hymowitz, S. G.; Tsui, V.; Deshayes, K.; Fairbrother, W. J.; Flygare, J. A.; Vucic, D. Antagonism of c-IAP and XIAP proteins is required for efficient induction of cell death by small-molecule IAP antagonists ACS Chem. Biol. 2009, 4, 557-566